drugset / Trial / NCT06059326

Multiple-dose Study to Evaluate the Safety,Tolerability, Pharmacokinetics and Pharmacodynamics of HSK7653 in T2DM

NCT06059326

Phase 2 Completed 48 enrolled Haisco Pharmaceutical Group Co., Ltd.
RandomizedSequentialDouble-blindTreatment

Summary

To evaluate the safety, tolerability and pharmacokinetic (PK)/pharmacodynamic (PD) characteristics of HSK7653 tablets in Type 2 Diabetes Mellitus Patients.

Timeline

Start
2019-01-22
Primary completion
2019-11-05
Completion
2019-11-05

Drugs

EvaluationDrugModalityDoseRoute
Subject HSK7653 Unknown 10 mg
Subject HSK7653 Unknown 25 mg
Subject HSK7653 Unknown 50 mg